MDPHP: Complete Human Toxicology, Fatalities, Metabolism & Dependence Monograph

MDPHP: Complete Human Toxicology, Fatalities, Metabolism & Dependence Monograph

Emergency stimulant toxicity: Dangerous overheating, severe agitation/confusion, chest pain, seizure, collapse, extreme weakness, very fast/irregular heartbeat, loss of consciousness, or behavior that cannot be safely controlled after an unknown stimulant requires urgent medical care.

Quick answer

MDPHP is 3,4-methylenedioxy-alpha-pyrrolidinohexanophenone, a pyrrolidinophenone synthetic cathinone related to MDPV and alpha-PHP.

It is no longer a sparse, anecdote-only research chemical.

The human evidence now includes:

• multiple analytically confirmed intoxication cases;
• authentic human metabolism;
• an isolated fatal intoxication;
• additional polydrug fatalities;
• postmortem tissue/distribution data;
• modern forensic work showing why MDPHP must be separated from its structural isomer MDPiHP.

The literature still does not establish a safe dose, universal half-life, impairment threshold, or dependence rate.

Identity

History and market emergence

MDPHP belongs to the methylenedioxy-pyrrolidinophenone series that includes:

• MDPPP;
• MDPBP;
• MDPV;
• MDPHP.

As controls on earlier cathinones expanded, longer-chain and positional analogues appeared in European and international NPS markets.

By 2019, MDPHP was appearing in enough clinical/forensic cases for a dedicated nine-case human investigation and metabolism study.

DEA toxicology surveillance subsequently detected it in U.S. biological samples.

Pharmacology

Direct controlled MDPHP receptor/transporter pharmacology is less mature than for MDPV or alpha-PVP.

Its structure and the broader pyrrolidinophenone literature support stimulant activity driven primarily by monoamine reuptake inhibition, especially dopamine and norepinephrine systems.

That is consistent with reported effects such as:

• agitation;
• paranoia/hallucinations;
• tachycardia;
• hypertension;
• chest pain;
• compulsive/repetitive behavior.

What should not be inferred

Structural similarity to MDPV does not establish:

• an MDPV-equivalent dose;
• identical potency;
• identical duration;
• a safe concentration.

Human intoxication evidence

Nine analytically confirmed cases

A 2020 investigation described nine cases associated with MDPHP use.

Serum concentrations varied widely.

All cases also involved other psychoactive drugs, frequently including:

• opioids;
• benzodiazepines.

Clinical presentations included:

• aggressive behavior;
• delayed physical responses;
• loss of consciousness;
• coma.

Because of the co-exposures, those symptoms cannot be assigned cleanly to MDPHP alone.

2024 acute-intoxication series

A newer clinical/analytical report added further acute MDPHP intoxication evidence and emphasized a syndrome that can include:

• hallucinations/paranoia;
• tachycardia;
• hypertension;
• chest pain;
• rhabdomyolysis.

Fatal intoxication without another causative co-drug

A 2022 forensic case described a 48-year-old man who died after acute MDPHP intoxication.

The authors presented it as the first reported lethal acute MDPHP intoxication without another co-ingested drug accounting for the death.

This is high-value evidence because it establishes intrinsic lethal potential with less polysubstance confounding than most NPS deaths.

2025 postmortem-distribution case

A separate fatality study measured MDPHP across:

• central blood;
• peripheral blood;
• vitreous humor;
• urine;
• gastric contents;
• hair.

The reported central and peripheral blood concentrations were both around 1.6 µg/mL, while urine and gastric concentrations were much higher.

The authors considered MDPHP the probable cause of death.

Postmortem redistribution

Central and peripheral blood were similar in that case, suggesting little postmortem redistribution for that individual.

One case cannot establish a universal redistribution pattern.

Polydrug fatality

A 2025 fatal case involved:

• MDPHP;
• clonazepam;
• lower levels of MDPPP, MDPV and MDPBP;
• citalopram.

The medical examiner attributed death to acute multidrug intoxication involving MDPHP and clonazepam.

The lower methylenedioxy-cathinone findings may have reflected synthesis impurities or additional exposure.

This case demonstrates why "drug detected" and "drug caused death" are separate forensic questions.

Acute toxicity

Potential severe stimulant toxicity includes:

• extreme agitation;
• panic/paranoia;
• hallucinations or psychosis;
• hypertension;
• tachycardia;
• chest pain;
• hyperthermia;
• seizures;
• rhabdomyolysis;
• kidney injury;
• loss of consciousness;
• cardiovascular collapse.

Polysubstance exposure can create mixed presentations that do not look like a simple stimulant toxidrome.

Hyperthermia and rhabdomyolysis

Pyrrolidinophenone stimulants can drive:

• intense sympathetic activation;
• prolonged activity/agitation;
• dehydration;
• overheating.

These can lead to:

• muscle breakdown;
• acute kidney injury;
• metabolic abnormalities.

Rhabdomyolysis has been reported in the MDPHP clinical literature.

Psychiatric toxicity

Potential effects include:

• paranoia;
• hallucinations;
• stimulant-induced psychosis;
• panic;
• disorganized behavior.

Sleep deprivation and repeated redosing can worsen psychiatric instability.

Cardiovascular toxicity

Reported and class-supported risks include:

• tachycardia;
• hypertension;
• chest pain;
• arrhythmia;
• cardiovascular collapse.

No validated MDPHP blood concentration defines when these become likely.

Human metabolism

The 2020 study used authentic human urine and identified:

• seven phase-I metabolites;
• three phase-II glucuronides.

The metabolic pattern was consistent with other alpha-pyrrolidinophenones.

Relevant pathways include:

• hydroxylation;
• reduction;
• pyrrolidine-ring transformations;
• further oxidation;
• glucuronidation.

Metabolites can improve confirmation when parent concentrations are low.

Pharmacokinetics

Despite increasing casework, controlled human MDPHP pharmacokinetics remain poorly defined.

There is no robust human program establishing a universal:

• bioavailability;
• time to peak;
• terminal half-life;
• clearance;
• repeated-use accumulation.

Postmortem concentrations cannot fill that gap.

Drug testing

Routine screens

Standard amphetamine/cocaine immunoassays do not specifically identify MDPHP.

A negative routine screen cannot rule it out.

Definitive testing

Published investigations use:

• LC-MS/MS;
• LC-HRMS/QTOF;
• GC-MS;
• Orbitrap-based methods;
• parent plus metabolite targets.

MDPHP vs MDPiHP: the isomer problem

MDPHP and MDPiHP are structural isomers.

They can produce closely similar analytical signals.

A 2026 forensic study validated chromatographic separation and warned that laboratories should:

• separate the isomers when possible;
• explicitly disclose unresolved co-elution when they cannot.

Why this matters

Incorrect isomer assignment can distort:

• death statistics;
• concentration references;
• epidemiology;
• causal interpretation.

Forensic concentration interpretation

Fatal concentration is not lethal dose

The 2022 and 2025 deaths provide case concentrations.

They do not establish a universal fatal range.

Intoxication and fatality concentrations can overlap

For stimulant NPS generally, severity depends on:

• timing;
• tolerance;
• co-drugs;
• individual physiology;
• specimen type;
• survival interval.

Interactions

No controlled MDPHP interaction studies define safe combinations.

High-risk contexts include:

• other stimulants → greater cardiovascular/hyperthermic stress;
• MAO inhibitors → potentially dangerous monoaminergic amplification;
• benzodiazepines/alcohol → mixed impairment and masking of warning signs;
• opioids → respiratory depression from the opioid component.

The human MDPHP literature contains frequent sedative/opioid co-exposure, so mixed intoxication is not theoretical.

Tolerance

Repeated stimulant exposure can produce tolerance to some subjective effects.

No MDPHP-specific human tolerance timeline is established.

Subjective tolerance does not guarantee protection from:

• hypertension;
• hyperthermia;
• psychosis;
• arrhythmia;
• sleep-deprivation toxicity.

Dependence and stimulant use disorder

Pyrrolidinophenones can have high reinforcement/compulsive-use potential.

MDPHP-specific dependence incidence has not been quantified.

Warning signs include:

• craving;
• repeated redosing;
• inability to cut down;
• long binges;
• continued use despite psychiatric or cardiovascular harm;
• neglect of responsibilities.

Stimulant withdrawal

After frequent stimulant use, withdrawal/post-use symptoms can include:

• fatigue;
• hypersomnia or insomnia;
• depressed mood;
• anhedonia;
• irritability;
• slowed thinking;
• increased appetite;
• craving.

No validated MDPHP-specific withdrawal onset/peak/duration exists.

Severe depression, suicidality, persistent psychosis, or inability to care for oneself warrants medical attention.

Treatment and support

There is no medication approved specifically for MDPHP use disorder.

The ASAM/AAAP stimulant-use-disorder guideline identifies contingency management as a core evidence-based behavioral intervention, often combined with cognitive-behavioral or community-reinforcement approaches.

Acute severe toxicity requires emergency treatment directed at complications such as:

• hyperthermia;
• seizure;
• cardiovascular instability;
• rhabdomyolysis;
• severe agitation.

U.S. resources include FindTreatment.gov and SAMHSA 1-800-662-HELP (4357).

Special populations

Controlled MDPHP data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• kidney disease;
• seizure disorders;
• psychotic/bipolar disorders.

The stimulant/hyperthermia profile makes cardiovascular and renal vulnerability particularly concerning.

Legal status — dated October 3, 2026

UNODC tracks MDPHP as a synthetic cathinone NPS.

This review did not identify a UN convention scheduling decision specifically placing MDPHP under international control.

The current U.S. federal schedules reviewed here also do not list MDPHP by name as a separately scheduled substance.

Potential federal analogue-law and state-law treatment can still apply depending on structure, intended human consumption and jurisdiction.

Myths and misconceptions

"MDPHP is just MDPV with a slightly longer chain."
Chemically related, yes; clinically interchangeable, no.

"No clean controlled trial means there is no proof it can kill."
False. Isolated/predominant fatal MDPHP cases are published.

"The highest fatal concentration is the lethal threshold."
False.

"A routine amphetamine screen rules it out."
False.

"MDPHP and MDPiHP are the same toxicology result."
False. They are distinct structural isomers and require analytical separation.

"Tolerance makes binge use safer."
Not established and potentially dangerous.

Evidence ledger

Related evidence

• MDPiHP
• alpha-PHP
• alpha-PiHP
• alpha-PVP
• N-Ethylhexedrone
• Synthetic cathinones & RC stimulants
• Substance Use, Dependence & Harm Reduction hub

Bottom line

MDPHP has crossed the threshold from obscure RC chemistry into a substance with a meaningful human toxicology record.

The evidence now includes real intoxication cases, authentic human metabolites, isolated and polydrug fatalities, postmortem distribution, and a modern analytical solution to the MDPHP/MDPiHP isomer problem.

That is enough to define serious risk—and still not enough to justify a safe-dose, half-life, or fatal-level chart.